ArticleBMC women's health2025
Cardiometabolic markers and serum amh levels in PCOS: can AMH serve as a surrogate cardiometabolic markeR?
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Two decades of nutrition research in polycystic ovary syndrome: emerging patterns and scientific output (2004-2024).Frontiers in nutrition · 2026Pooled it
- Lipid accumulation product and visceral adiposity index in polycystic ovary syndrome: a systematic review and meta-analysis of observational studies.Lipids in health and disease · 2025Pooled it
- Visceral Adiposity Index (VAI) Levels and Metabolic Risk Across Phenotypes of Polycystic Ovary Syndrome (PCOS).Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the cardiometabolic markers in women in with polycystic ovary syndrome (PCOS) across all phenotypes and its correlation with serum anti-mullerian hormone (AMH) levels. METHODOLOGY: In cross-sectional community-based study aimed to determine the prevalence of PCOS among women aged 19-39 years over 5 years (2018-2022), 10,109 women were found to be eligible from 14,061 approached through a pre validated questionnaire. Out of this cohort, 201 women were diagnosed prior, and from the 2314 probable cases on detailed clinical, ultrasound and hormonal evaluation as per Rotterdam criteria, 860 were true cases. Healthy women from the same community matched for age and BMI, were taken as controls (1174). Both PCOS and healthy controls were assessed for cardio-metabolic indices, including anthropometry (BMI, Waist Circumference (WC), Waist to Hip Ratio (WHR), biochemistry (OGTT with 75 g glucose, lipid profile, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), visceral adiposity index [VAI], lipid accumulation product [LAP]) and fasting and post prandial insulin. Other hormone assays and AMH levels were also assessed in PCOS and controls. Correlation between serum AMH and cardiometabolic indices was calculated for cases using Pearson's method. Data was analysed using STATA version 18. MAIN OUTCOME MEASURE(S): Cardio-metabolic profile including obesity/overweight, hypertension, insulin resistance, dyslipidemia among PCOS women and their different phenotypes, comparison with controls and correlation with serum AMH levels in cases. RESULT(S): In the baseline characteristics, PCOS group had higher systolic and diastolic blood pressure, fasting blood sugar, 2 h oral glucose tolerance test (OGTT), fasting, 30 min and two hours post OGTT insulin levels than control group. In lipid profile, PCOS group had lower High Density Lipoprotein-Cholestrol (HDL-C) and higher low Density Lipoprotein-Cholestrol (LDL-C) levels. HOMA-IR, VAI, LAP were significantly higher in PCOS group. When AMH was correlated with various cardio-metabolic indices in women with PCOS, significant positive correlation was found with BMI, waist circumference, triglycerides and very low Density Lipoprotein cholestrol (VLDL-C) VLDL levels. While correlating AMH with cardio-metabolic indices in different phenotypes, PCOS phenotype A, C, and D suggested a significant positive correlation with BMI, waist circumference, post -prandial blood sugar at 30 min and VLDL-C, while phenotype B correlated only with BMI and VLDL levels. CONCLUSION(S): A positive correlation could be seen between serum AMH and anthropometric and lipid profile parameters in Indian PCOS women. No such correlation can be established between other insulin resistance markers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.